ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 001936

Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography

Identifieur interne : 001936 ( PascalFrancis/Corpus ); précédent : 001935; suivant : 001937

Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography

Auteurs : S. Lehericy ; J.-P. Brandel ; E. C. Hirsch ; P. Anglade ; J. Villares ; D. Scherman ; C. Duyckaerts ; F. Javoy-Agid ; Y. Agid

Source :

Brain research [ 0006-8993 ] ; 1994.

RBID : Pascal:94-0677079

Descripteurs français

Pascal (Inist)
- Exploration, Parkinson maladie, Démence Alzheimer, Corps strié, Dopamine, Neurone dopaminergique, Etude comparative, Autoradiographie, Homme.

English descriptors

KwdEn :
- Alzheimer disease, Autoradiography, Comparative study, Corpus striatum, Dopamine, Dopaminergic neuron, Exploration, Human, Parkinson disease.

Abstract

The monoaminergic innervation of the caudate nucleus, putamen and ventral striatum was investigated post mortem, in patients with Parkinson's and Alzheimer's disease as compared to control subjects, by autoradiographic detection of tritiated dihydrotetrabenazine (³H-TBZOH), a specific high affinity ligand of the vesicular monoamine transporter. The binding of ³H-TBZOH was specific and saturable (K_d 5.3 nM). In control striatum, the pattern of distribution of ³H-TBZOH binding was heterogeneous, with higher binding levels in the «matrix» than in the «striosome» compartment. Changes in ligand binding levels were observed in the pathological brains compared to controls. In Parkinson's disease (PD), characterized by a severe damage of mesostriatal dopaminergic neurons, the density of ³H-TBZOH binding was reduced

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0006-8993`
A02	`01`			`@0 BRREAP`
A03		`1`		`@0 Brain res.`
A05				`@2 659`
A06				`@2 1-2`
A08	`01`	`1`	`ENG`	`@1 Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography`
A11	`01`	`1`		`@1 LEHERICY (S.)`
A11	`02`	`1`		`@1 BRANDEL (J.-P.)`
A11	`03`	`1`		`@1 HIRSCH (E. C.)`
A11	`04`	`1`		`@1 ANGLADE (P.)`
A11	`05`	`1`		`@1 VILLARES (J.)`
A11	`06`	`1`		`@1 SCHERMAN (D.)`
A11	`07`	`1`		`@1 DUYCKAERTS (C.)`
A11	`08`	`1`		`@1 JAVOY-AGID (F.)`
A11	`09`	`1`		`@1 AGID (Y.)`
A14	`01`			`@1 INSERM, U 289 lab. médecine exp. @2 Paris @3 FRA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 8 aut. @Z 9 aut.`
A14	`02`			`@1 Rhône-Poulenc Rorer @2 94403 Vitry sur Seine @3 FRA @Z 6 aut.`
A14	`03`			`@1 Hôp. Salpêtrière, lab. neuropathologie @2 Paris @3 FRA @Z 7 aut.`
A20				`@1 1-9`
A21				`@1 1994`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 12895 @5 354000041405480010`
A44				`@0 0000`
A45				`@0 45 ref.`
A47	`01`	`1`		`@0 94-0677079`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Brain research`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 The monoaminergic innervation of the caudate nucleus, putamen and ventral striatum was investigated post mortem, in patients with Parkinson's and Alzheimer's disease as compared to control subjects, by autoradiographic detection of tritiated dihydrotetrabenazine (³H-TBZOH), a specific high affinity ligand of the vesicular monoamine transporter. The binding of ³H-TBZOH was specific and saturable (K_d 5.3 nM). In control striatum, the pattern of distribution of ³H-TBZOH binding was heterogeneous, with higher binding levels in the «matrix» than in the «striosome» compartment. Changes in ligand binding levels were observed in the pathological brains compared to controls. In Parkinson's disease (PD), characterized by a severe damage of mesostriatal dopaminergic neurons, the density of ³H-TBZOH binding was reduced
C02	`01`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Exploration @5 01`
C03	`01`	`X`	`ENG`	`@0 Exploration @5 01`
C03	`01`	`X`	`SPA`	`@0 Exploración @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinson maladie @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Démence Alzheimer @2 NM @5 03`
C03	`03`	`X`	`ENG`	`@0 Alzheimer disease @2 NM @5 03`
C03	`03`	`X`	`SPA`	`@0 Demencia Alzheimer @2 NM @5 03`
C03	`04`	`X`	`FRE`	`@0 Corps strié @5 04`
C03	`04`	`X`	`ENG`	`@0 Corpus striatum @5 04`
C03	`04`	`X`	`SPA`	`@0 Cuerpo estriado @5 04`
C03	`05`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 05`
C03	`05`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 05`
C03	`05`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 05`
C03	`06`	`X`	`FRE`	`@0 Neurone dopaminergique @5 06`
C03	`06`	`X`	`ENG`	`@0 Dopaminergic neuron @5 06`
C03	`06`	`X`	`SPA`	`@0 Neurona dopaminérgica @5 06`
C03	`07`	`X`	`FRE`	`@0 Etude comparative @5 09`
C03	`07`	`X`	`ENG`	`@0 Comparative study @5 09`
C03	`07`	`X`	`GER`	`@0 Vergleich @5 09`
C03	`07`	`X`	`SPA`	`@0 Estudio comparativo @5 09`
C03	`08`	`X`	`FRE`	`@0 Autoradiographie @5 11`
C03	`08`	`X`	`ENG`	`@0 Autoradiography @5 11`
C03	`08`	`X`	`GER`	`@0 Autoradiographie @5 11`
C03	`08`	`X`	`SPA`	`@0 Autorradiografía @5 11`
C03	`09`	`X`	`FRE`	`@0 Homme @5 41`
C03	`09`	`X`	`ENG`	`@0 Human @5 41`
C03	`09`	`X`	`SPA`	`@0 Hombre @5 41`
C07	`01`	`X`	`FRE`	`@0 Maladie dégénérative @5 20`
C07	`01`	`X`	`ENG`	`@0 Degenerative disease @5 20`
C07	`01`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 20`
C07	`02`	`X`	`FRE`	`@0 Système nerveux pathologie @5 21`
C07	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 21`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 21`
C07	`03`	`X`	`FRE`	`@0 Noyau gris central @5 26`
C07	`03`	`X`	`ENG`	`@0 Basal ganglion @5 26`
C07	`03`	`X`	`SPA`	`@0 Núcleo basal @5 26`
C07	`04`	`X`	`FRE`	`@0 Encéphale @5 27`
C07	`04`	`X`	`ENG`	`@0 Brain (vertebrata) @5 27`
C07	`04`	`X`	`SPA`	`@0 Encéfalo @5 27`
C07	`05`	`X`	`FRE`	`@0 Système nerveux central @5 28`
C07	`05`	`X`	`ENG`	`@0 Central nervous system @5 28`
C07	`05`	`X`	`SPA`	`@0 Sistema nervioso central @5 28`
C07	`06`	`X`	`FRE`	`@0 Neurotransmetteur @5 29`
C07	`06`	`X`	`ENG`	`@0 Neurotransmitter @5 29`
C07	`06`	`X`	`SPA`	`@0 Neurotransmisor @5 29`
C07	`07`	`X`	`FRE`	`@0 Catécholamine @5 30`
C07	`07`	`X`	`ENG`	`@0 Catecholamine @5 30`
C07	`07`	`X`	`SPA`	`@0 Catecolamina @5 30`
N21				`@1 338`

Format Inist (serveur)

NO :	PASCAL 94-0677079 INIST
ET :	Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography
AU :	LEHERICY (S.); BRANDEL (J.-P.); HIRSCH (E. C.); ANGLADE (P.); VILLARES (J.); SCHERMAN (D.); DUYCKAERTS (C.); JAVOY-AGID (F.); AGID (Y.)
AF :	INSERM, U 289 lab. médecine exp./Paris/France (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 8 aut., 9 aut.); Rhône-Poulenc Rorer/94403 Vitry sur Seine/France (6 aut.); Hôp. Salpêtrière, lab. neuropathologie/Paris/France (7 aut.)
DT :	Publication en série; Niveau analytique
SO :	Brain research; ISSN 0006-8993; Coden BRREAP; Pays-Bas; Da. 1994; Vol. 659; No. 1-2; Pp. 1-9; Bibl. 45 ref.
LA :	Anglais
EA :	The monoaminergic innervation of the caudate nucleus, putamen and ventral striatum was investigated post mortem, in patients with Parkinson's and Alzheimer's disease as compared to control subjects, by autoradiographic detection of tritiated dihydrotetrabenazine (³H-TBZOH), a specific high affinity ligand of the vesicular monoamine transporter. The binding of ³H-TBZOH was specific and saturable (K_d 5.3 nM). In control striatum, the pattern of distribution of ³H-TBZOH binding was heterogeneous, with higher binding levels in the «matrix» than in the «striosome» compartment. Changes in ligand binding levels were observed in the pathological brains compared to controls. In Parkinson's disease (PD), characterized by a severe damage of mesostriatal dopaminergic neurons, the density of ³H-TBZOH binding was reduced
CC :	002B17G
FD :	Exploration; Parkinson maladie; Démence Alzheimer; Corps strié; Dopamine; Neurone dopaminergique; Etude comparative; Autoradiographie; Homme
FG :	Maladie dégénérative; Système nerveux pathologie; Noyau gris central; Encéphale; Système nerveux central; Neurotransmetteur; Catécholamine
ED :	Exploration; Parkinson disease; Alzheimer disease; Corpus striatum; Dopamine; Dopaminergic neuron; Comparative study; Autoradiography; Human
EG :	Degenerative disease; Nervous system diseases; Basal ganglion; Brain (vertebrata); Central nervous system; Neurotransmitter; Catecholamine
GD :	Vergleich; Autoradiographie
SD :	Exploración; Parkinson enfermedad; Demencia Alzheimer; Cuerpo estriado; Dopamina; Neurona dopaminérgica; Estudio comparativo; Autorradiografía; Hombre
LO :	INIST-12895.354000041405480010
ID :	94-0677079

Links to Exploration step

Pascal:94-0677079

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography</title>
<author><name sortKey="Lehericy, S" sort="Lehericy, S" uniqKey="Lehericy S" first="S." last="Lehericy">S. Lehericy</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 289 lab. médecine exp.</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brandel, J P" sort="Brandel, J P" uniqKey="Brandel J" first="J.-P." last="Brandel">J.-P. Brandel</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 289 lab. médecine exp.</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E. C." last="Hirsch">E. C. Hirsch</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 289 lab. médecine exp.</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Anglade, P" sort="Anglade, P" uniqKey="Anglade P" first="P." last="Anglade">P. Anglade</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 289 lab. médecine exp.</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Villares, J" sort="Villares, J" uniqKey="Villares J" first="J." last="Villares">J. Villares</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 289 lab. médecine exp.</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Scherman, D" sort="Scherman, D" uniqKey="Scherman D" first="D." last="Scherman">D. Scherman</name>
<affiliation><inist:fA14 i1="02"><s1>Rhône-Poulenc Rorer</s1>
<s2>94403 Vitry sur Seine</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Duyckaerts, C" sort="Duyckaerts, C" uniqKey="Duyckaerts C" first="C." last="Duyckaerts">C. Duyckaerts</name>
<affiliation><inist:fA14 i1="03"><s1>Hôp. Salpêtrière, lab. neuropathologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Javoy Agid, F" sort="Javoy Agid, F" uniqKey="Javoy Agid F" first="F." last="Javoy-Agid">F. Javoy-Agid</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 289 lab. médecine exp.</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 289 lab. médecine exp.</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">94-0677079</idno>
<date when="1994">1994</date>
<idno type="stanalyst">PASCAL 94-0677079 INIST</idno>
<idno type="RBID">Pascal:94-0677079</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001936</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography</title>
<author><name sortKey="Lehericy, S" sort="Lehericy, S" uniqKey="Lehericy S" first="S." last="Lehericy">S. Lehericy</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 289 lab. médecine exp.</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brandel, J P" sort="Brandel, J P" uniqKey="Brandel J" first="J.-P." last="Brandel">J.-P. Brandel</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 289 lab. médecine exp.</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E. C." last="Hirsch">E. C. Hirsch</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 289 lab. médecine exp.</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Anglade, P" sort="Anglade, P" uniqKey="Anglade P" first="P." last="Anglade">P. Anglade</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 289 lab. médecine exp.</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Villares, J" sort="Villares, J" uniqKey="Villares J" first="J." last="Villares">J. Villares</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 289 lab. médecine exp.</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Scherman, D" sort="Scherman, D" uniqKey="Scherman D" first="D." last="Scherman">D. Scherman</name>
<affiliation><inist:fA14 i1="02"><s1>Rhône-Poulenc Rorer</s1>
<s2>94403 Vitry sur Seine</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Duyckaerts, C" sort="Duyckaerts, C" uniqKey="Duyckaerts C" first="C." last="Duyckaerts">C. Duyckaerts</name>
<affiliation><inist:fA14 i1="03"><s1>Hôp. Salpêtrière, lab. neuropathologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Javoy Agid, F" sort="Javoy Agid, F" uniqKey="Javoy Agid F" first="F." last="Javoy-Agid">F. Javoy-Agid</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 289 lab. médecine exp.</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 289 lab. médecine exp.</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Brain research</title>
<title level="j" type="abbreviated">Brain res.</title>
<idno type="ISSN">0006-8993</idno>
<imprint><date when="1994">1994</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Brain research</title>
<title level="j" type="abbreviated">Brain res.</title>
<idno type="ISSN">0006-8993</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer disease</term>
<term>Autoradiography</term>
<term>Comparative study</term>
<term>Corpus striatum</term>
<term>Dopamine</term>
<term>Dopaminergic neuron</term>
<term>Exploration</term>
<term>Human</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Exploration</term>
<term>Parkinson maladie</term>
<term>Démence Alzheimer</term>
<term>Corps strié</term>
<term>Dopamine</term>
<term>Neurone dopaminergique</term>
<term>Etude comparative</term>
<term>Autoradiographie</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The monoaminergic innervation of the caudate nucleus, putamen and ventral striatum was investigated post mortem, in patients with Parkinson's and Alzheimer's disease as compared to control subjects, by autoradiographic detection of tritiated dihydrotetrabenazine (<sup>3</sup>
H-TBZOH), a specific high affinity ligand of the vesicular monoamine transporter. The binding of <sup>3</sup>
H-TBZOH was specific and saturable (K<sub>d</sub>
 5.3 nM). In control striatum, the pattern of distribution of <sup>3</sup>
H-TBZOH binding was heterogeneous, with higher binding levels in the «matrix» than in the «striosome» compartment. Changes in ligand binding levels were observed in the pathological brains compared to controls. In Parkinson's disease (PD), characterized by a severe damage of mesostriatal dopaminergic neurons, the density of <sup>3</sup>
H-TBZOH binding was reduced</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0006-8993</s0>
</fA01>
<fA02 i1="01"><s0>BRREAP</s0>
</fA02>
<fA03 i2="1"><s0>Brain res.</s0>
</fA03>
<fA05><s2>659</s2>
</fA05>
<fA06><s2>1-2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LEHERICY (S.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BRANDEL (J.-P.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HIRSCH (E. C.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>ANGLADE (P.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>VILLARES (J.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SCHERMAN (D.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>DUYCKAERTS (C.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>JAVOY-AGID (F.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>AGID (Y.)</s1>
</fA11>
<fA14 i1="01"><s1>INSERM, U 289 lab. médecine exp.</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Rhône-Poulenc Rorer</s1>
<s2>94403 Vitry sur Seine</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Hôp. Salpêtrière, lab. neuropathologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>1-9</s1>
</fA20>
<fA21><s1>1994</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>12895</s2>
<s5>354000041405480010</s5>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>45 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>94-0677079</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Brain research</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The monoaminergic innervation of the caudate nucleus, putamen and ventral striatum was investigated post mortem, in patients with Parkinson's and Alzheimer's disease as compared to control subjects, by autoradiographic detection of tritiated dihydrotetrabenazine (<sup>3</sup>
H-TBZOH), a specific high affinity ligand of the vesicular monoamine transporter. The binding of <sup>3</sup>
H-TBZOH was specific and saturable (K<sub>d</sub>
 5.3 nM). In control striatum, the pattern of distribution of <sup>3</sup>
H-TBZOH binding was heterogeneous, with higher binding levels in the «matrix» than in the «striosome» compartment. Changes in ligand binding levels were observed in the pathological brains compared to controls. In Parkinson's disease (PD), characterized by a severe damage of mesostriatal dopaminergic neurons, the density of <sup>3</sup>
H-TBZOH binding was reduced</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Exploration</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Exploration</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Exploración</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Démence Alzheimer</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Alzheimer disease</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Demencia Alzheimer</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Corps strié</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Corpus striatum</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Cuerpo estriado</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Neurone dopaminergique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Dopaminergic neuron</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Neurona dopaminérgica</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="GER"><s0>Vergleich</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Autoradiographie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Autoradiography</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="GER"><s0>Autoradiographie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Autorradiografía</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>41</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>41</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>41</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>20</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>21</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>21</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>21</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Noyau gris central</s0>
<s5>26</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Basal ganglion</s0>
<s5>26</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Núcleo basal</s0>
<s5>26</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>27</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Brain (vertebrata)</s0>
<s5>27</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>27</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>28</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>28</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>28</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>29</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>29</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>29</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>30</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>30</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>30</s5>
</fC07>
<fN21><s1>338</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 94-0677079 INIST</NO>
<ET>Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography</ET>
<AU>LEHERICY (S.); BRANDEL (J.-P.); HIRSCH (E. C.); ANGLADE (P.); VILLARES (J.); SCHERMAN (D.); DUYCKAERTS (C.); JAVOY-AGID (F.); AGID (Y.)</AU>
<AF>INSERM, U 289 lab. médecine exp./Paris/France (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 8 aut., 9 aut.); Rhône-Poulenc Rorer/94403 Vitry sur Seine/France (6 aut.); Hôp. Salpêtrière, lab. neuropathologie/Paris/France (7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Brain research; ISSN 0006-8993; Coden BRREAP; Pays-Bas; Da. 1994; Vol. 659; No. 1-2; Pp. 1-9; Bibl. 45 ref.</SO>
<LA>Anglais</LA>
<EA>The monoaminergic innervation of the caudate nucleus, putamen and ventral striatum was investigated post mortem, in patients with Parkinson's and Alzheimer's disease as compared to control subjects, by autoradiographic detection of tritiated dihydrotetrabenazine (<sup>3</sup>
H-TBZOH), a specific high affinity ligand of the vesicular monoamine transporter. The binding of <sup>3</sup>
H-TBZOH was specific and saturable (K<sub>d</sub>
 5.3 nM). In control striatum, the pattern of distribution of <sup>3</sup>
H-TBZOH binding was heterogeneous, with higher binding levels in the «matrix» than in the «striosome» compartment. Changes in ligand binding levels were observed in the pathological brains compared to controls. In Parkinson's disease (PD), characterized by a severe damage of mesostriatal dopaminergic neurons, the density of <sup>3</sup>
H-TBZOH binding was reduced</EA>
<CC>002B17G</CC>
<FD>Exploration; Parkinson maladie; Démence Alzheimer; Corps strié; Dopamine; Neurone dopaminergique; Etude comparative; Autoradiographie; Homme</FD>
<FG>Maladie dégénérative; Système nerveux pathologie; Noyau gris central; Encéphale; Système nerveux central; Neurotransmetteur; Catécholamine</FG>
<ED>Exploration; Parkinson disease; Alzheimer disease; Corpus striatum; Dopamine; Dopaminergic neuron; Comparative study; Autoradiography; Human</ED>
<EG>Degenerative disease; Nervous system diseases; Basal ganglion; Brain (vertebrata); Central nervous system; Neurotransmitter; Catecholamine</EG>
<GD>Vergleich; Autoradiographie</GD>
<SD>Exploración; Parkinson enfermedad; Demencia Alzheimer; Cuerpo estriado; Dopamina; Neurona dopaminérgica; Estudio comparativo; Autorradiografía; Hombre</SD>
<LO>INIST-12895.354000041405480010</LO>
<ID>94-0677079</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001936 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001936 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:94-0677079
   |texte=   Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography

Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri